Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$97.46 USD

97.46
477,516

+0.88 (0.91%)

Updated Sep 9, 2024 04:00 PM ET

After-Market: $97.49 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (205 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View

Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.

Can Canadian Market Drive Canopy Growth (CGC) Q2 Earnings?

Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.

BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat

A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.

Wright Medical (WMGI) Reports Q3 Loss, Raises '18 Guidance

Growth in the upper and the lower extremity segments drives Wright Medical's (WMGI) Q3 results

Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up

Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.

Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates

We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.

DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down

DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.

Hologic (HOLX) Q4 Earnings Miss, Revenues Top Estimates

Tough year-over-year comparisons and soft Diagnostics sales hurt Hologic's (HOLX) performance in Q4.

Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag

Myriad Genetics (MYGN) witnesses strong performance by GeneSight, EndoPredict, and Prolaris tests in Q1.

Nabaparna Bhattacharya headshot

Cardinal Health (CAH) Surpasses Earnings Estimates in Q1

Cardinal Health (CAH) Q1 results benefit from strong sales in the Pharmaceutical and the Medical segments.

STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y

STERIS (STE) continues to gain from strength in all business segments in Q2.

Luminex's (LMNX) Q3 Earnings and Revenues Miss Estimates

Luminex (LMNX) gains from segmental contributions in Q3; margins contract.

CVS Health's (CVS) Q3 Earnings Top Estimate, Gross Margin Up

CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.

Becton, Dickinson (BDX) Q4 Earnings Beat, FY19 View Strong

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4; fiscal 2019 guidance solid.

AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View

AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4.

Henry Schein's (HSIC) Q3 Earnings Top, Revenues Lag Estimates

All four of Henry Schein's (HSIC) operating segments recording year-over-year growth in Q3 encourages us.

PRA Health's (PRAH) Q3 Earnings Top, Revenues Lag Estimates

PRA Health (PRAH) posts year-over-year double-digit growth in earnings, revenues and net new business in Q3. However, increasing labor-related costs in the Clinical Research wing are a concern.

CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3

Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.

Hill-Rom (HRC) Q4 Earnings Top Estimates on All-Line Growth

Hill-Rom (HRC) benefits from a robust year-over-year revenue increase on solid domestic growth in Q4, driven by a strong segmental performance at both Patient Support Systems and Front Line Care.

Integer Holdings (ITGR) Beats on Q3 Earnings and Revenues

Integer Holdings (ITGR) gains from solid Medical sales contribution in Q3; 2018 guidance solid.

Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates

Significant margin contraction hurts Allscripts' (MDRX) results in Q3; decline in bookings discourages.

Tandem Diabetes (TNDM) Reports Loss in Q3, Revenues Beat

Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.

Masimo (MASI) Beats on Q3 Earnings, 2018 Guidance Impressive

Masimo (MASI) gains from strong Product revenues in Q3; raises 2018 outlook.

Abiomed (ABMD) Q2 Earnings Beat, Impella Maintains Momentum

Abiomed's (ABMD) flagship Impella sees a solid Q2; fiscal 2019 outlook raised.